Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05493319 | Hypopressive Exercise Associated With Strength and Resistance Training in Women Treated for Gynecological Cancer | unknown | N/A | 36 | Universidade Federal de Sao CarlosOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04995731 | Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer | unknown | — | 328 | Assiut UniversityOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | unknown | Phase 2 | 132 | Xiaohua Wu MDOTHER | 0 | Jul 29, 2022 | clinicaltrials |
| NCT04903665 | PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I | unknown | — | 495 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05475847 | Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer(TIL) | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02562365 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer(ACTS) | unknown | Phase 2 | 130 | Xiaohua Wu MDOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT04845425 | Analysis of miRNA Expression in Endometrial Cancer(MIRCE) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05467319 | Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS(FORGE) | unknown | Phase 3 | 82 | Alberta Health Services, CalgaryOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05203562 | Letrozole as a Prophylaxis From GTN for Complete Mole Patients | unknown | Phase 2 / Phase 3 | 200 | Zagazig UniversityOTHER_GOV | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05440578 | First-line Olaparib Combined With Bevacizumab Maintenance Therapy | unknown | — | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT04864431 | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer(VitD) | unknown | N/A | 54 | Indonesia UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05410015 | Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05410028 | New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence | unknown | — | 1,000 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT02639650 | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | unknown | Phase 3 | 214 | Weiguo LvOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04812002 | Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy | unknown | Phase 2 | 20 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04742543 | Virtual Reality During Conization of Cervix Uterus Under Local Anesthesia | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04756713 | Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia(ReCure) | unknown | Phase 3 | 150 | Brigham and Women's HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387460 | Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT04772001 | Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer | unknown | N/A | 53 | Zhongnan HospitalOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02494791 | Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer(LS2) | unknown | N/A | 886 | University Health Network, TorontoOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05375526 | Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer | unknown | N/A | 10 | Maastricht University Medical CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT04235556 | Integrated Care Pathway in Oncology (PASSION)(PASSION) | unknown | — | 1,800 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT05371301 | Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer | unknown | Phase 3 | 200 | Fudan UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04856306 | Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L(Magical) | unknown | — | 300 | Medstar Health Research InstituteOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT04866394 | Stereotactic Pelvic Adjuvant Radiation TherApy in Cancers of the UteruS(SPARTACUS) | unknown | N/A | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05362669 | SMS Messaging for Invitation in the Cervical Cancer Screening Programme(CERCA-SMS) | unknown | N/A | 450 | Institut Català d'OncologiaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05359913 | Podcasting Cervical Cancer Prevention for AAW | unknown | N/A | 40 | University of HoustonOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT02067052 | New Strategy for the Treatment of Vulvar Cancer | unknown | — | 44 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05314907 | Acceptability of Self-sampling for Cervical Cancer Screening | unknown | N/A | 1,614 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05273099 | Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma | unknown | — | 8 | Università degli Studi di FerraraOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT05310305 | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer | unknown | — | 20 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05316376 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05309122 | Cervical Cancer Screening Strategies | unknown | — | 10,000 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2022source: clinicaltrials